Menu Back toLaunching Megatrials During a Pandemic: Lessons Learned from COVID-19 Vaccine Clinical Trials
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Launching Megatrials During a Pandemic: Lessons Learned from COVID-19 Vaccine Clinical Trials
Lindsay McNair, MD, MPH, MS
- Chief Medical Officer
- WCG, United States
As drug development moves toward precision and targeted medicines, megatrials which include tens of thousands of participants are uncommon. But the developers of COVID-19 vaccines launched complex trials of this size in 2020, encountering not just the challenges of massive clinical trials but also those of running clinical trials during the pandemic. In this forum, senior-level executives from biopharma companies which conducted COVID-19 vaccine trials will discuss the experience of clinical operations in this context, sharing what they expected and did not expect, lessons learned, and what they will take forward to the conduct of future research.
Learning Objective : Describe some of the unique challenges of launching extremely large clinical trials; Discuss unique and innovative practices and solutions that clinical teams developed to manage these challenges; Assess ideas for best practices that can be applied to future clinical trial conduct.
Melanie Ivarsson, PhD, MBA
- Chief Development Officer
- Moderna, United States
Dawn M Furey
- Vice President, Portfolio Delivery Operations
- Janssen, United States
- Vice President, Clinical Operations Head – Vaccines
- Pfizer Inc, United States